[Screening for prostate cancer--what does the evidence show?].
A recent Cochrane review of the available randomised evidence for screening for prostate cancer is referred and discussed. The review concludes that there is insufficient evidence to either support or refute the routine use of mass, selective or opportunistic screening compared to no screening in order to reduce prostate cancer mortality. Until ongoing large, randomised screening trials mature and produce results that may prove otherwise, the Danish policy of not recommending PSA-based screening should be upheld.
Borre
Michael
M
Arhus Universitetshospital, Skejby. borre@dadlnet.dk
Iversen
Peter
P
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen